> Hi-Tech Pharmacal got the FDA's OK to sell its version of Dermik Laboratories' Penlac nail fungus treatment.
Millipore is expanding on its reputation as a filtration supplier to scientific labs around the globe. Known for purified water and filters, Millipore has leveraged several buyouts to increase its
Researchers for Sosei say that a Phase II trial for an experimental therapy for fibromyalgia failed to hit its primary endpoint, but researchers were quick to highlight encouraging signs of the
Boston-based Third Rock Ventures has launched a fund with $378 million of committed capital that will be used to invest in life sciences companies at the early stages of formation. Third Rock said it
At this weekâ€™s Bear Stearns Healthcare Conference, Pfizer discussed its plans for the future with analysts. As we all know, Pfizer is facing a major loss of sales when its best-selling drug
When does good news feel almost bad? When a blockbuster drug is deemed the juiciest on the market--but the wolves are circling. If this sounds like Lipitor to you, you're right. Today, the Pfizer
These are good times for PTC Therapeutics, one of this year's Fierce 15. Just after being
Here's an important note from the Bear Stearns Healthcare Conference: Expect to see Pfizer snapping up biologics from smaller drug developers and investing more money in biotech companies in the
> GlaxoSmithKline has boosted its supply of flu vaccine for the U.S. market by up to 10 million doses this season, to 30 to 35 million from 25 million last flu season.
Throw a bunch of pharma execs into a room with financial analysts, and what do you get? Almost unmitigated hope. Thinking positive is a must when analysts are around, so as industry leaders stand up